Skip to main content
. 2016 Apr 4;113(16):4470–4475. doi: 10.1073/pnas.1525349113

Fig. S2.

Fig. S2.

Dual cediranib+MEDI3617 therapy increases the development of early necrosis in U87 tumors. Mice bearing U87 tumors were treated with control (green bar), MEDI3617 (orange bar), cediranib (red bar), or dual therapy (blue bar). H&E-stained tissues were analyzed for the area of diffuse hypoxic changes (early necrosis). *Dual therapy significantly increased early necrosis in U87 tumors compared with cediranib- (P = 0.0039), MEDI3617- (P = 0.043) and control-treated (P = 0.0026) tumors. Error bars represent the SEM.